Article Text

PDF
AB0667 Biological Therapy for Psoriatic Arthritis in Clinical Practice
  1. J. Paccou1,
  2. A.-S. Soubrier2,
  3. P. Philippe2,
  4. B. Cortet2,
  5. R.-M. Flipo2
  1. 1Rheumatology, INSERM U1088, Université de Picardie Jules Verne, Amiens
  2. 2Rheumatology, University hospital of Lille, Lille, France

Abstract

Objectives To evaluate the performance of anti-TNF drugs in psoriatic arthritis (PsA) in a routine care setting.

Methods Observational study conducted in PsA patients recruited from a tertiary rheumatology clinic in the North of France. PsA was classified according to the CASPAR and/or Moll and Wright criteria. Inclusion criteria were patients with PsA who started infliximab, etanercept, adalimumab or golimumab therapy between April 2001 and December 2012, followed for up to 6 months. Treatment of peripheral forms was considered to be effective when the patients obtained a favorable expert opinion or >30% clinical improvement of swollen and tender joint counts. Treatment of axial forms was considered to be effective for an improvement in BASDAI of at least 2 on a scale of 0-10 or 50% improvement (BASDAI 50) or favorable expert opinion. Drug survival of the first anti-TNF was investigated and drug survival was compared between patients with and without cs-DMARD co-medication and between infliximab, etanercept and adalimumab. Cox regression was used to identify predictors of discontinuation of the first anti-TNF drug.

Results The study included 193 patients (107/86 M/F, mean age 46.8 yrs, mean disease duration 6.7 yrs, 171/22 peripheral/axial forms). Only 48 (25%) were on a concomitant cs-DMARDs (65% on methotrexate). The majority of patients were started on first-line etanercept (n=102), followed by adalimumab (n=46), infliximab (n=44) and golimumab (n=1). At 3 months, 90% of patients had obtained an adequate response, 7% had discontinued due to lack of efficacy and 3% due to adverse events. Significantly decreased values for swollen and tender joints, BASDAI, erythrocyte sedimentation rate and C-reactive protein were observed within 3 months after initiation of first anti-TNF (p<0.01 for all). Median drug survival was 2.0 years [0.1-15.7], and 1-year and 2-year drug survival rates were 77% and 67%, respectively. The crude retention rates were similar among patients receiving infliximab, adalimumab, and etanercept (p>0.05). Drug survival was not superior in patients receiving co-medication (p>0.05). Discontinuation was reported in 95 patients (49%) and, on Cox regression analysis, previous cardiovascular disease was an independent predictor of discontinuation of the first anti-TNF (odds ratio [OR] 5.02, 95%CI: 1.06-23.9, p=0.04). Seventy nine (41%) patients switched to a second anti-TNF and 29 to a third anti-TNF; 80% of switchers responded to second-line and 83% responded to third-line therapy.

Conclusions In these patients receiving their first anti-TNF for PsA treated in routine clinical practice, high drug adherence and response rates were observed and pre-existing cardiovascular disease was an independent predictor of discontinuation. Moreover, 80% of patients obtained a response to second- or third-line anti-TNF after having failed one or two anti-TNF drugs.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.2368

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.